Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network

OBJECTIVES: Pazopanib received US Food and Drug Administration approval in 2009 for advanced renal cell carcinoma. During clinical development, liver chemistry abnormalities and adverse hepatic events were observed, leading to a boxed warning for hepatotoxicity and detailed label prescriber guidelin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Patient Saf
Main Authors: Shantakumar, Sumitra, Nordstrom, Beth L., Hall, Susan A., Djousse, Luc, van Herk-Sukel, Myrthe P.P., Fraeman, Kathy H., Gagnon, David R., Chagin, Karen, Nelson, Jeanenne J.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407814/
https://ncbi.nlm.nih.gov/pubmed/28430700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PTS.0000000000000332
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados